FLI1 and systemic sclerosis: Similar to bosentan, our latest paper demonstrated that imatinib reverses the decreased expression of Fli1 in SSc dermal fibroblasts by increasing its protein stability and without affecting its gene expression status [33], suggesting that imatinib is a potential disease-modifying drug for SSc patients.